Cargando…
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
Inhibition of deubiquitinase (DUB) activity is a promising strategy for cancer therapy. VLX1570 is an inhibitor of proteasome DUB activity currently in clinical trials for relapsed multiple myeloma. Here we show that VLX1570 binds to and inhibits the activity of ubiquitin-specific protease-14 (USP14...
Autores principales: | Wang, Xin, Mazurkiewicz, Magdalena, Hillert, Ellin-Kristina, Olofsson, Maria Hägg, Pierrou, Stefan, Hillertz, Per, Gullbo, Joachim, Selvaraju, Karthik, Paulus, Aneel, Akhtar, Sharoon, Bossler, Felicitas, Khan, Asher Chanan, Linder, Stig, D’Arcy, Padraig |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893612/ https://www.ncbi.nlm.nih.gov/pubmed/27264969 http://dx.doi.org/10.1038/srep26979 |
Ejemplares similares
-
Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
por: Wang, Xin, et al.
Publicado: (2016) -
Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570
por: Pellegrini, Paola, et al.
Publicado: (2020) -
Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition
por: Mazurkiewicz, Magdalena, et al.
Publicado: (2017) -
Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System
por: Selvaraju, Karthik, et al.
Publicado: (2021) -
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
por: Rowinsky, Eric K., et al.
Publicado: (2020)